SCHEMBL5376202

SCHEMBL5376202

O=C1NC(Cc2ccc(OCc3ccccc3)cn2)C(=O)NC1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 1/20 0.48
HRH3 Q9Y5N1 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4C Q9H3R0 1/20 0.45
TNKS2 Q9H2K2 2/20 0.41
CREBBP Q92793 1/20 0.41
ALOX5 P09917 1/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
GSTP1 P09211 1/20 0.40
MMP13 P45452 1/20 0.40
IP6K1 Q92551 1/20 0.40
NSD2 O96028 1/20 0.40
ABL1 P00519 1/20 0.40
PPARG P37231 1/20 0.40
RIN1 Q13671 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5375510 0.97 HRH3 (0.50) P4HTMHRH3MEN1KMT2AKDM4C
SCHEMBL4658615 0.97 P4HTM (0.50) P4HTMHRH3MEN1KMT2AKDM4C
SCHEMBL5379438 0.94 LMNA (0.48) P4HTMHRH3MEN1KMT2AKDM4C
SCHEMBL5374989 0.93 HRH3 (0.44) P4HTMHRH3MEN1KMT2AKDM4C
SCHEMBL5392310 0.93 MMP1 (0.47) P4HTMHRH3MEN1KMT2AKDM4C
SCHEMBL5379659 0.93 EGFR (0.44) P4HTMHRH3MEN1KMT2AKDM4C
SCHEMBL5381466 0.91 MAPK1 (0.46) P4HTMHRH3MEN1KMT2ATNKS2
SCHEMBL14400075 0.87 HRH3 (0.50) HRH3KMT2AKDM4CPPARGL3MBTL1
SCHEMBL5380505 0.86 HSD17B10 (0.42) P4HTMHRH3MEN1KMT2AKDM4C
SCHEMBL5374807 0.86 P4HTM (0.41) P4HTMHRH3MEN1KMT2AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288545-B2 Piperazinedione compounds ANGIORX CORPORATION (TW) 2007-10-30 US disclosed
US-7288545-B2 Piperazinedione compounds ANGIORX CORPORATION (TW) 2007-10-30 US disclosed
US-20040132738-A1 Piperazinedione compounds ANGIORX CORPORATION (TW) 2004-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132738-A1 Piperazinedione compounds CBR1, KDR, FLT1 P4HTM 1191/4885HRH3 549/4885MEN1 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.